We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.93B
1-Year Est. Return 160.8%
This Fund
S&P 500
This Quarter Est. Return
+32.66%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$1.98B
AUM Growth
+$533M
Cap. Flow
+$154M
Cap. Flow %
7.75%
Top 10 Hldgs %
47.31%
Holding
123
New
37
Increased
37
Reduced
31
Closed
16

Top Buys

Rank Stock Value
1
AVTR icon
Avantor
AVTR
+$27.7M
2
GSK icon
GSK
GSK
+$26.1M
3
ABVX
Abivax
ABVX
+$25.2M
4
EXAS
Exact Sciences
EXAS
+$19.4M
5
DHR icon
Danaher
DHR
+$19.1M

Top Sells

Rank Stock Value
1
ZIMV
ZimVie
ZIMV
+$39.4M
2
NTRA icon
Natera
NTRA
+$38.6M
3
QURE icon
uniQure
QURE
+$31.4M
4
RVTY icon
Revvity
RVTY
+$22.2M
5
TEVA icon
Teva Pharmaceuticals
TEVA
+$17.3M

Sector Composition

Rank Sector Weight
1 Healthcare 89.79%
2 Miscellaneous 10.13%
3 Financials 0.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VERA icon
1
Vera Therapeutics
VERA
$2.59B
$156M 7.84%
3,072,304
+264,468
+9% +$9.39M
QQQ icon
2
PUT
Invesco QQQ Trust
QQQ
$490B
$138M 6.97%
225,000
-5,000
-2% -$3.07M
GSK icon
3
GSK
GSK
$100B
$131M 6.62%
2,679,721
+559,275
+26% +$26.1M
UTHR icon
4
United Therapeutics
UTHR
$20.9B
$123M 6.2%
252,592
-628
-0.2% -$292K
ABVX
5
Abivax
ABVX
$10B
$88.7M 4.47%
657,834
+231,335
+54% +$25.2M
NTRA icon
6
Natera
NTRA
$47.3B
$76.6M 3.86%
334,493
-185,151
-36% -$38.6M
SNDX icon
7
Syndax Pharmaceuticals
SNDX
$1.84B
$69.6M 3.51%
3,314,408
-152,906
-4% -$2.67M
VRDN icon
8
Viridian Therapeutics
VRDN
$2.6B
$55.5M 2.79%
1,782,235
-142,071
-7% -$3.9M
PCVX icon
9
Vaxcyte
PCVX
$9.1B
$55.3M 2.78%
1,197,722
-224,261
-16% -$10M
TVTX icon
10
Travere Therapeutics
TVTX
$6.15B
$44.9M 2.26%
1,174,968
-242,236
-17% -$7.88M
HCA icon
11
HCA Healthcare
HCA
$87.7B
$44.8M 2.26%
95,874
-15,826
-14% -$7.35M
DHR icon
12
Danaher
DHR
$146B
$42.6M 2.15%
186,262
+86,989
+88% +$19.1M
IONS icon
13
Ionis Pharmaceuticals
IONS
$9.65B
$42.6M 2.15%
538,218
-443
-0.1% -$33.4K
CLDX icon
14
Celldex Therapeutics
CLDX
$3.12B
$39M 1.96%
1,434,725
+280,805
+24% +$7.4M
BRKR icon
15
Bruker
BRKR
$8.91B
$36.9M 1.86%
783,789
+96,660
+14% +$4.08M
AVTR icon
16
Avantor
AVTR
$10.1B
$36.4M 1.83%
3,176,644
+2,252,202
+244% +$27.7M
SPY icon
17
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$814B
$30.6M 1.54%
+44,900
New +$30.3M
CYH icon
18
Community Health Systems
CYH
$408M
$24.8M 1.25%
7,943,802
+993,751
+14% +$3.34M
EXAS
19
DELISTED
Exact Sciences
EXAS
$24.5M 1.24%
+241,678
New +$19.4M
BCRX icon
20
BioCryst Pharmaceuticals
BCRX
$2.55B
$23.3M 1.18%
2,992,895
+1,619,270
+118% +$11.7M
GERN icon
21
Geron
GERN
$1.01B
$23.3M 1.17%
17,659,983
+5,060,981
+40% +$6.35M
TECH icon
22
Bio-Techne
TECH
$11.4B
$22.2M 1.12%
377,405
-214,135
-36% -$13M
CDTX
23
DELISTED
Cidara Therapeutics
CDTX
$21.8M 1.1%
+98,721
New +$16M
PODD icon
24
Insulet
PODD
$10.2B
$21.2M 1.07%
74,708
+29,104
+64% +$9.1M
BBNX
25
Beta Bionics
BBNX
$874M
$20.7M 1.04%
+678,262
New +$18.1M
1
2 3 4 5

Similar funds

SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return
RIA
Regal Investment Advisors Kentwood, Michigan $1.92B AUM 23.13% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $1.92B AUM 45.54% 1-Year Est. Return
DCP
Distillate Capital Partners Chicago, Illinois $1.92B AUM 5.31% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
GIA
Guyasuta Investment Advisors Pittsburgh, Pennsylvania $1.94B AUM 32.92% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

Eversept Partners's Q4 2025 Portfolio in Review

As of Q4 2025, Eversept Partners held 123 positions worth $1.98B, up 37% from $1.45B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Eversept Partners deployed $154M of net new capital in Q4 2025, opening 37 new positions and adding to 37 existing holdings. Its largest new stake was Exact Sciences: 241,678 shares worth $24.5M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, down from 90% a quarter earlier, followed by Miscellaneous and Financials.

On the sell side, the largest reduction was Natera, an estimated $38.6M trimmed.

  • Eversept Partners's largest Q4 2025 buy was Exact Sciences: 241,678 shares worth $24.5M.
  • Eversept Partners added most to Avantor in Q4 2025, an estimated $27.7M increase.
  • Eversept Partners's biggest Q4 2025 reduction was Natera, cutting an estimated $38.6M.
  • Eversept Partners fully exited ZimVie in Q4 2025, selling an estimated $39.4M.
  • Eversept Partners's ten largest holdings make up 47% of its $1.98B portfolio in Q4 2025.
  • Eversept Partners opened 37 new positions and closed 16 in Q4 2025.
  • Eversept Partners's portfolio value rose 37% quarter-over-quarter to $1.98B.

Based on Eversept Partners's 13F filing for Q4 2025, filed 17 Feb 2026.